ESHRE PAGES What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium steering committee†

Joyce Harper1,12, Edith Coonen2, Martine De Rycke3, Francesco Fiorentino4, Joep Geraedts2, Veerle Goossens5, Gary Harton6, Celine Moutou7, Tugce Pehlivan Budak8, Pam Renwick9, Sioban SenGupta1, Joanne Traeger-Synodinos10, and Katerina Vesela11 UCL Centre for PG&D, Institute for Women’s Health, University College London, 86-96 Chenies Mews, WC1E6HX London, UK Department of Clinical Genetics, PGD working group Maastricht, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands Centre for Medical Genetics, UZ Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium GENOMA, Molecular Genetics Laboratory, Via Po, 102, 00198 Rome, Italy ESHRE Central Office, Meerstraat 60, 1852 Grimbergen, Belgium Genetics & IVF Institute, 3015 Williams Drive, Fairfax, VA 22031, USA Service de la Biologie de la Reproduction, SIHCUS-CMCO, 19, Rue Louis Pasteur, BP120, 67303 Schiltigheim, France Instituto Valenciano de Infertilidad (IVI), Istanbul, Oya Sokak No:23a, 34387 Mecidiyekoy, Istanbul, Turkey Centre for PGD, Guy’s Hospital, Great Maze Pond, SE1 9RT London, UK Department of Medical Genetics, University of Athens, St. Sophia’s Children’s Hospital, Athens 11527, Greece Sanatorium Repromeda, Vinicni 235, 615 00 Brno, Czech Republic Correspondence address. E-mail: [email protected]